跳到正文
原文
Medical Xpress·· 24 天前精选AI 评分64

WEHI研究发现移除SMCHD1可重启Prader-Willi综合征中沉默的基因

Switching on healthy silent genes reveals new way to treat Prader-Willi syndrome

AI 导读

WEHI研究团队在Science Advances发表研究,发现移除蛋白SMCHD1可解除基因沉默,使Prader-Willi综合征中休眠的健康基因重新表达。研究结合CRISPR基因编辑、干细胞与基因组技术,在患者来源干细胞和小鼠脑组织中观察到基因活性恢复,研究团队表示这一过程未干扰身体其他部分。

推荐理由

研究在患者来源干细胞与小鼠脑组织中观察到移除SMCHD1可重启沉默基因,为靶向病因的早期开发提供线索。

正文
Switching on healthy silent genes reveals new way to treat rare genetic disorder
Blue staining shows gene activity in mouse brain tissue after SMCHD1 was removed (right). The finding demonstrates a new way to reactivate healthy genes that are normally silenced in Prader-Willi syndrome. Credit: Walter and Eliza Hall Institute of Medical Research

WEHI researchers have discovered a way to release a genetic 'brake' that silences healthy genes in Prader-Willi syndrome, opening a potential new path to treating the condition.

About 400,000 people worldwide live with Prader-Willi syndrome, a complex and devastating condition that affects the brain, causing lifelong physical and developmental challenges.

In a new study, researchers showed that removing a protein called SMCHD1 lifts a genetic 'brake,' allowing healthy but dormant genes to switch back on. The findings are published in the journal Science Advances.

The discovery offers hope for a treatment that targets the underlying cause of Prader-Willi syndrome and is now being advanced toward potential new medicines through WEHI spinout company Togglelux Therapeutics.

How dormant genes were reactivated in Prader-Willi syndrome

Discovered at WEHI in 2008, SMCHD1 is a protein that helps regulate gene activity.

In Prader-Willi syndrome, it switches off certain genes essential for development and brain function—contributing to symptoms like developmental delays, intellectual disability and an insatiable appetite that can lead to obesity.

People with Prader-Willi syndrome often rely on multiple medications, surgeries and specialist care, but these treatments address symptoms rather than the cause, providing limited relief.

In the new study, the team combined CRISPR gene-editing, stem-cell and genomic technologies to track what happened when SMCHD1 was removed, measuring the effects across thousands of genes and in the most disease-relevant brain tissue.

Lead researcher Marnie Blewitt said one of the study's most important findings was that gene activity could be restored without causing problems elsewhere in the body, a critical step toward developing future treatments for babies and young children.

"We thought reactivating the 'sleeping' genes might be possible—what we didn't know was whether we could do it safely," said Blewitt, deputy director of WEHI and head of the epigenetics laboratory.

"We now have the strongest evidence that removing SMCHD1 can restore gene activity lost in Prader-Willi syndrome without disrupting the rest of the body."

Why a safe and effective Prader-Willi treatment matters

Blewitt works closely with families affected by the condition and hears firsthand the challenges patients and caregivers face every day.

"I've seen children undergo multiple surgeries for scoliosis and met families whose lives revolve around medications, specialist appointments and managing often life-threatening symptoms," she said.

"Prader-Willi is one of the most complex medical conditions a family can face. That's why the possibility of a treatment that targets the root cause, rather than symptoms, is so significant."

Prader-Willi Research Foundation Australia CEO Kathlene Jones said the findings are an important step toward treatments that target the root cause of the condition.

"Most people can't conceive what daily life is like for a person living with Prader-Willi syndrome," she said.

"Our children and adults have to navigate a world full of food they can't eat, while feeling an intense drive to consume it. That relentless pressure can bring great distress and very challenging behaviors that affect the whole family.

"A treatment that addresses the root cause of the disease would be transformational. It could ease that burden for people living with PWS and bring relief to their families and caregivers.

"While still at an early stage, Blewitt's work is a testament to what can be achieved when scientists and small, family-led patient organizations collaborate."

Homegrown discovery progresses toward potential new Prader-Willi treatment

The new findings are the culmination of nearly two decades of research led by Blewitt, marking an important milestone in a uniquely Australian scientific journey that began with her team's discovery of SMCHD1 in 2008.

"This is my life's work, so it's incredibly rewarding to finally see this approach succeed and bring hope to patients," said Blewitt.

"Watching those dormant genes 'wake up' in both patient-derived stem cells and animal models was a powerful confirmation that the strategy works.

"It's exciting to see a fundamental discovery that began at WEHI now being developed locally and advancing toward potential new medicines, with the ultimate goal of helping those affected by this complex condition."

Publication details

Megan Iminitoff et al., SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome, Science Advances (2026). DOI: 10.1126/sciadv.aej5702

Journal information: Science Advances

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Switching on healthy silent genes reveals new way to treat Prader-Willi syndrome (2026, October 27) retrieved 27 October 2026 from https://medicalxpress.com/news/2026-10-healthy-silent-genes-reveals-prader.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com